![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1391958
¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀå : ½ÃÇè À¯Çüº°, ÇÁ·Î¼¼½º ÄÄÆ÷³ÍÆ®º°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°Bioprocess Validation Market, By Test Type, By Process Component, By End User, By Geography |
¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀå ±Ô¸ð´Â 2023³â 8¾ï 8,240¸¸ ´Þ·¯¿¡¼ 2030³â 4¾ï 6,090¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ¿¹Ãø ±â°£ µ¿¾È CAGR 9.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ ¼¼ºÎÁ¤º¸ | ||
---|---|---|---|
±âÁسâ | 2022³â | ½ÃÀå ±Ô¸ð(2023³â) | 4¾ï 6,090¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2018-2021³â | ¿¹Ãø ±â°£ | 2023-2030³â |
¿¹Ãø ±â°£ÀÇ CAGR | 9.70% | ½ÃÀå ±Ô¸ð ¿¹Ãø(2030³â) | 8¾ï 8,240¸¸ ´Þ·¯ |
¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥À̼ÇÀº ¼³°è ´Ü°èºÎÅÍ »ó¾÷ »ý»ê¿¡ À̸£±â±îÁö µ¥ÀÌÅ͸¦ ¼öÁýÇÏ°í Æò°¡Çϸç, ÇÁ·Î¼¼½º°¡ ÀϰüµÇ°Ô °íǰÁúÀÇ Á¦Ç°À» Á¦°øÇÒ ¼ö ÀÖ´Ù´Â °úÇÐÀû ±Ù°Å¸¦ È®¸³ÇÏ´Â °ÍÀÔ´Ï´Ù. ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶ÀÇ ±ÔÁ¦ ¿ä°ÇÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀåÀº »ý¹°Á¦Á¦¿Í ´ÜŬ·ÐÇ×ü ¼ö¿ä Áõ°¡¿¡ °ßÀεǾî ÃÖ±Ù ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ´Ù¾çÇÑ Ä¡·á ¿µ¿ª¿¡¼ ȯÀÚÀÇ Ä¡·á¿Í °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Åµ´Ï´Ù. »ý¹° Á¦Á¦ÀÇ ½ÂÀΰú »ý»ê Áõ°¡´Â ÀÌ·¯ÇÑ º¹ÀâÇÑ ºÐÀÚÀÇ Ç°Áú, È¿´É ¹× ¾ÈÀü¼ºÀ» º¸ÀåÇÏ´Â °ËÁõ Ȱµ¿À» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(US FDA)À» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ±ÔÁ¦±â°üÀÌ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥À̼ǿ¡ ¾ö°ÝÇÑ ±ÔÁ¦¸¦ ¸¶·ÃÇϰí ÀÖ¾î ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀåÀÇ ¼ºÀåÀº ¾÷°è »óȲÀ» Çü¼ºÇÏ´Â ´Ù¾çÇÑ ¿äÀε鿡 ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¹ÙÀÌ¿À ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ¾ÏÀ̳ª ÀÚ°¡¸é¿ªÁúȯ µî ¸¸¼ºÁúȯÀÇ ¸¸¿¬ÀÌ ÁøÇàµÊ¿¡ µû¶ó ¼±ÁøÀûÀÎ »ý¹°Á¦Á¦°¡ °³¹ßµÇ°Ô µÇ¾î °ß°íÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç Àü·«ÀÇ Çʿ伺ÀÌ »ý±â°í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ¶Ç ´Ù¸¥ ¿äÀÎÀº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)°ú À¯·´ÀǾàû(EMA)°ú °°Àº ±ÔÁ¦´ç±¹ÀÌ ºÎ°úÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦´Â ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶¾÷ü¿¡°Ô Á¦Á¶ °øÁ¤ÀÇ È¿´É°ú Àϰü¼ºÀ» ÀÔÁõÇÒ °ÍÀ» ¿ä±¸Çϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
°Ô´Ù°¡ ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ Àμö µî ¹«±âÀûÀΠȰµ¿ÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ¿¹Ãø ±â°£¿¡ ÀÖ¾î¼ÀÇ ¼¼°è ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥ÀÌ¼Ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 4¿ù ¼¼°è »ý¸í°úÇÐÀÇ Çõ½ÅÀÚÀÎ Danaher CorporationÀº »ý¹°Á¦Á¦ °³¹ß ¹× Á¦Á¶ ¼Ö·ç¼ÇÀ» °ÈÇϱâ À§ÇØ General ElectricÀÇ »ý¸í°úÇÐ ºÎ¹®¿¡¼ Å©·Î¸¶Åä±×·¡ÇÇ ½Ã½ºÅÛÀ» Æ÷ÇÔÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º »ç¾÷À» ÀμöÇß½À´Ï´Ù.
±×·¯³ª ½ÃÀå¿¡´Â ¸î °¡Áö ¾ïÁ¦¿äÀεµ ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ º¹ÀâÇÑ ¼ºÁú°ú Ç¥ÁØÈµÈ ¹ë¸®µ¥ÀÌ¼Ç ÇÁ·ÎÅäÄÝÀÇ °á¿©°¡ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½ºÀÇ °³¹ß ¹× ¹ë¸®µ¥À̼ǿ¡´Â ½Ã°£ÀÌ °É¸®°í ÀÚ¿ø°ú ÀÎÇÁ¶ó Ãø¸é¿¡¼ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. °Ô´Ù°¡, ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¹ë¸®µ¥À̼ǿ¡ Àͼ÷ÇÑ ¼÷·ÃµÈ Àü¹®°¡°¡ ºÎÁ·ÇÏ´Ù´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ½ÃÀå¿¡´Â ¸î °¡Áö ¼ºÀå ±âȸ°¡ ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ÀÚµ¿È ¹× µ¥ÀÌÅÍ ºÐ¼®ÀÇ ±â¼úÀû Áøº¸´Â ¹ë¸®µ¥ÀÌ¼Ç ÇÁ·Î¼¼½º¸¦ °£¼ÒÈÇÏ°í ºñ¿ë Àý°¨ ¹× È¿À²¼º Çâ»óÀ» ±â´ëÇÕ´Ï´Ù. °Ô´Ù°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡¿Í ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º¿¡¼ÀÇ ´ÜÀÏ »ç¿ë ±â¼úÀÇ Ã¤Åà Áõ°¡´Â ½ÃÀå È®´ëÀÇ »õ·Î¿î ±æÀ» Á¦°øÇÕ´Ï´Ù.
The Bioprocess Validation Market size is expected to reach US$ 460.9 million by 2030, from US$ 882.4 million in 2023, growing at a CAGR of 9.7% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 460.9 Mn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: | 9.70% | 2030 Value Projection: | US$ 882.4 Mn |
Bioprocess validation is the collection and evaluation of data, from the design stage through commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality product. It is a regulatory requirement for biopharmaceuticals manufacturing. The bioprocess validation market has been witnessing significant growth in recent years driven by the increasing demand for biologics and monoclonal antibodies. Biologics have revolutionized patient care and treatments across various therapeutic areas. Rising biologics approvals and production have been propelling validation activities to guarantee the quality, efficacy, and safety of such complex molecules. Various regulatory agencies including the U.S. Food and Drug Administration (U.S. FDA) have stringent regulations for bioprocess validation, facilitating the growth of this market.
The bioprocess validation market growth is driven by various factors that are shaping the industry landscape. One of the primary drivers is the increasing demand for biopharmaceutical products. The growing prevalence of chronic diseases, such as cancer and autoimmune disorders, has led to the development of advanced biologics, thereby creating a need for robust bioprocess validation strategies.
Another factor contributing to market growth is the stringent regulations imposed by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulations require biopharmaceutical manufacturers to demonstrate the effectiveness and consistency of their manufacturing processes, driving the demand for bioprocess validation.
Moreover, the increasing adoption of inorganic activities such as acquisition by the market players is expected to drive the growth of the global bioprocess validation market over the forecast period. For instance, in April 2020, Danaher Corporation, a global life sciences and diagnostic innovator, acquired the bioprocessing business from General Electric's life sciences division, including chromatography systems, to enhance biologics development and manufacturing solutions.
However, the market does face some restraints. The complex nature of bioprocessing and the lack of standardized validation protocols pose challenges. The development and validation of bioprocesses are time-consuming and require substantial investments in terms of resources and infrastructure. Additionally, the scarcity of skilled professionals with expertise in bioprocess validation further impedes market growth.
Despite these challenges, the market experiences several opportunities for growth. Technological advancements in bioprocess automation and data analytics are anticipated to streamline the validation process, reducing costs and enhancing efficiency. Furthermore, the increasing focus on personalized medicine and the rising adoption of single-use technologies in bioprocessing offer new avenues for the market expansion.
Bioprocess Validation Market Segmentation: